

**17th Annual John Goldman Conference on
Chronic Myeloid Leukemia: Biology and Therapy
Lisbon, Portugal
October 1-4, 2015**

These abstracts are presented in alphabetical order according to the name of the first author.

CLINICAL POSTERS

- POSTER 24: Evaluation of molecular response by digital droplet PCR in patients with CML UNDER TKIs therapy
Marcio Andrade-Campos, Pilar Alfonso, Laura Lopez de Frutos, Javier Gervas, Vanesa Andreu, Pilar Giraldo
- POSTER 25: Assesment of cardiovascular risk and cardiovascular events in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Paola Assunçao, Roberto Zulli, Marcia Delamain, Gislaine Duarte, Irene Lorand-Metze, Carmino de Souza, Katia Pagnano
- POSTER 26: Imatinib as first-line therapy for myeloid chronic leukemia; the mexican experience at Cmn "La Raza", IMSS
Manuel Ayala, Elsa Avila, Jacqueline Dominguez, Xochilt Aquino, Jorge Vela
- POSTER 27: Nilotinib in patients with chronic myeloid leukemia in all phases after imatinib resistance or intolerance: Cmn "La Raza" experience
Manuel Ayala, Elsa Avila, Jacqueline Dominguez, Xochilt Aquino, Jorge Vela
- POSTER 28: Dasatinib in patients with chronic myeloid leukemia in all phases in first line or after imatinib resistance; Cmn "La Raza" experience
Manuel Ayala, Elsa Avila, Xochitl Aquino, Jacqueline Dominguez, Jorge Vela
- POSTER 29: Mutation detection and dynamics of BCR-ABL mutated clones in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitors previously treated with imatinib
Raquel Bengio, Cristian Ferri, Alicia Enrico, Beatriz Moiragui, Analia Carvani, Marta Dragosky, Soledad Cruset, Matias Vukovic, Silvina Palmer, Claudia Shanley, Veronica Ventriglia, Maria Laura Rizzi, Patricia Murolo, Nazario Diaz Velez, Romina Mariano, Maria Josefina Freitas, Luis Beligoy, Michele Bianchini, Irene Larripa
- POSTER 30: BCR-ABL transcripts variations in chronic phase chronic myelogenous leukemia patients on imatinib: Possible role of the autologous immune system
Geoffrey Clapp, Thomas Lepoutre, Raouf El-Cheikh, Samuel Bernard, Jérémy Ruby, Helene Labuissiere-Wallet, Franck E. Nicolini, Levy Doron

- POSTER 31: Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the phase 2 PACE trial
Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H Jean Khoury, Moshe Talpaz, Daniel J. De Angelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian
- POSTER 32: Major route additional chromosomal aberrations (ACA) precede increase of blasts in CML: an analysis of the German CML-studies III and IIIa
Christian T. Dietz, Alice Fabarius, Michael Lauseker, Susanne Saussele, Lida Kalmenti, Sébastien Rinaldetti, Claudia Haferlach, Brigitte Schlegelberger, Martine Jotterand, Alois Gratwohl, Axel Zander, Nicolaus Kröger, Dietrich Beelen, Jürgen Novotny, Christoph Nerl, Christof Scheid, Karsten Spiekermann, Jiri Mayer, Herbert G Sayer, Christiane Falge, Donald Bunjes, Hartmut Döhner, Arnold Ganser, Peter Brossart, Rainer Schwerdtfeger, Herrad Baurmann, Rolf Kuse, Hans W. Lindemann, Matthias Bormann, Bernd Hertenstein, Gabriela M. Baerlocher, Carlo Aul, Peter Staib, Matthias Edinger, Michael Schatz, Axel Fauser, Renate Arnold, Dieter K. Hossfeld, Hans-Jochem Kolb, Susanne Schnittger, Martin C. Müller, Andreas Reiter, Andreas Hochhaus, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Rüdiger Hehlmann
- POSTER 33: Dasatinib is associated with reduced platelet function in chronic phase chronic myeloid leukaemia patients
Sebastian Francis
- POSTER 34: Center size, patient age, and co-medication do not impact molecular response to 1st-Line nilotinib treatment in CML: An analysis of the German patients enrolled into ENEST1st
Jakob Hammersen, Cristina Berger, Ekkehard Eigendorff, Thomas Schenk, Christian Fabisch, Andreas Hocchhaus, Paul La Rosée
- POSTER 35: Systematic review and meta-analysis of randomized trials comparing imatinib 400 mg/d vs. imatinib 800 mg/d, and imatinib 400 mg/d vs. second generation TKIs in chronic phase CML-patients
Verena Sophia Hoffmann, Joerg Hasford, Rudiger Hehlmann
- POSTER 36: Impact of the type of BCR-ABL fusion transcripts on response and survival in patients with chronic phase CML treated with four frontline TKI modalities
Preetesh Jain, Hagop Kantarjian, Rajyalakshmi Luthra, Graciela Noguera Gonzalez, Keyur P. Patel, Elias Jabbour, Koji Sasaki, Carlos Guillermo Romo, Tapan M. Kadia, Gautam Borthakur, Zeev Estrov, Farhard Ravandi, Susan O'Brien, Jorge Cortes
- POSTER 37: Age and cost are associated with preference for stopping tyrosine kinase inhibitor therapy in person with chronic myeloid leukemia
Qian Jiang, Zheng-Chen Liu, Song-Xin Zhang, Jing Li, Robert Peter Gale
- POSTER 38: Imatinib discontinuation in chronic myeloid leukemia: single US center experience
H. Jean Khoury

- POSTER 39: Comparison on frequency and sensitivity of baseline BCR-ABL kinase domain mutations in Asian and Caucasian patients with imatinib failure chronic phase chronic myeloid leukemia
Hawk Kim, Soo-Hyun Kim, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Jae-Yong Kwak, Ho-Yong Yhim, Sung Hyun Kim, Young Rok Do, Sukjoong Oh, Sung-Eun Lee, Saengsuree Jootar, Jiuwei Cui, Dong-Wook Kim
- POSTER 40: Effects of bosutinib dose escalation on gastrointestinal adverse-events
Vamsi Kota, Faud El Rassi, Martha Arellano, Leonard T. Heffner, Elliott F. Winton, Morgan McLemore, Anand Jillella, H. Jean Khoury
- POSTER 41: Pregnancy in chronic myeloid leukemia: Analysis of the 19 cases
Kostyantyn Kotlyarchuk, Anna Lukianova, Ekaterina Chelysheva, Zvenyslava Maslyak
- POSTER 42: Active imatinib uptake and its intracellular concentrations in granulocytes of CML patients
Eva Kralj, Simon Zakelj, Jurij Trontelj, Albin Kristl, Tadej Pajic, Peter Cernelc, Irena Preloznik Zupan
- POSTER 43: Relationship of line of therapy to efficacy for ponatinib in 3rd-line versus 4th-line chronic-phase chronic myeloid leukemia (CP-CML)
Moshe Yair Levy, Lisa J. McGarry, Stephanie Lustgarten, Mo Yang, Frank G. Haluska
- POSTER 44: High resolution melting (HRM) curve analysis as a screening technique for the detection of mutations in BCR/ABL kinase domain in imatinib resistant CML patients and correlation with sanger & next generation sequencing
Hemant Malhotra, Bharti Malhotra, Ajay Yadav, Shipra Bhargava, Pratibha Sharma
- POSTER 45: Clinical evaluation of Xpert® BCR-ABL ultra, an automated and standardized cartridge-based assay for the quantification of BCR-ABL
Michael Mauro, Richard Press, David Snyder, Qin Huang, Javier Pinilla-Ibarz, Dahui Qin, Christina Lockwood, Jacqueline Payton, Geoffrey Uy, Matt Kalaycio, Ramon Tiu, Vivian Oehler, Gwo-Jen Day, Wendy Wong, Michael Bates, Jerald Radich
- POSTER 46: RARE forms of presentation of chronic myeloid leukemia (CML)
Teresa Melo, Daniela Santos, Teresa Costa, Henrique Coelho
- POSTER 47: More than 9 years of chronic myeloid leukemia treated with imatinib - 2 cases of different lymphomas
Susana Isabel Mendes, Ana Rita Ferreira, Helena Martins, Fabiola Velosa, Lurdes Guerra, Conceicao Lopes, Maria Joao Costa, Blanca Polo, José Alves do Carmo
- POSTER 48: BCR-ABL gene mutations in imatinib resistant CML patients in our centre
Marica Pavkovic, Dijana Plashevaska-Karanfilska, Rosica Angelovic, Sonja Genadieva-Stavric, Oliver Karanfiski, Lidija Cevreska, Aleksandar Stojanovic
- POSTER 49: gDNA based real time PCR to detect ph positive cells independently from their transcription status
C. Pirrone, O. Spinelli, Ester Pungolino, Alessia Rainero, Andrea Conti, Giorgia Millefanti, S. Lilliu, T. Intermesoli, U. Giussani, S. Lupoli, F. D'Avila, M. Barcella, F. Bolda, R. Baffelli, F. Pasquali, F. Lo Curto, C. Barlassina, A. Rambaldi, F. Porta, A. Lanfranchi, Carmen Fava, Giuseppe Saglio, G. Porta

- POSTER 50: Minimal residual disease and withdrawal symptoms can predict successful imatinib-free remission in chronic myeloid leukemia
Young Rok Do, Sung-Eun Lee, Soo Young Choi, Hyeoung-Joon Kim, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Jang, Jinny Park, Dong-Wook Kim
- POSTER 51: Myeloid blast crisis of atypical CML & CML with $ider(22)(q10)t(9;22)(q34;q1112)$ as clonal evolution
Hun Mo Ryoo, SH Bae
- POSTER 52: Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country
Sheikh Ali
- POSTER 53: Improving patient adherence and outcomes by developing an interactive care map for Canadian CML patients based on ELN and NCCN guidelines for the treatment of CML
Cheryl-Anne Simoneau, Sandra Shaw
- POSTER 54: Complications of treatment a patient with atypical E6A2 BCR-ABL fusion transcript in a Philadelphia-positive CML
Lukas Stejskal, Cecilia Bodzasova, Zuzana Kucerova, Jana Laska, Marie Pencikova, Jiri Sobotka, Elena Tothova, Roman Hajek
- POSTER 55: First line tyrosine kinase inhibitor prescription in newly diagnosed chronic phase chronic myeloid leukemia in South Korea
Yaewon Yang, Youngil Koh, Seonyang Park, Inho Kim, Hyo Jung Kim, Hyun Jung Lee, Jeongok Lee, Ji-Hyun Kwon, Sung-Soo Yoon